海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-04-19
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-04-17
Authorised
- A Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease
- Inflammatory bowel disease (Crohn's disease) MedDRA version: 18.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Austria
- 2015-11-05
Authorised
- Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease. Subjects will be separated in two groups that will be treated in parallel to receive study drug or placebo. Neither the treating physician nor the subject will be aware of the actual treatment received.
- Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Bulgaria, Canada, Czech Republic, Israel, New Zealand, Poland, Romania, Serbia, Slovakia, United States
- 2015-06-01
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-04-20
Authorised
- Studio internazionale per il trattamento della leucemia linfoblastica acuta Philadelphia positiva
- Leucemia Linfoblastica Acuta Ph + MedDRA version: 20.1 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia System Organ Class: 100000004864 MedDRA version: 20.1 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, Chile, European Union, Hong Kong, Israel, Italy, Switzerland, United States
- 2018-02-12
Authorised
- Vitamin D and pharmakogenetics in glucose metabolism
- Polycystic Ovary Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Austria
- 2013-01-24
Authorised
- A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy
- Multiple Myeloma relapsing after one previous line therapy MedDRA version: 12.1 Level: LLT Classification code 10028228 Term: Multiple myeloma
- Austria, Czech Republic, France, Germany, Greece, Italy, Spain
- 2010-03-12
Authorised
- Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA)
- Advanced (locally advanced inoperable or metastatic) triple negative breast cancer progressing after first-line therapy;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria
- 2016-09-16
Authorised
- A Phase 3 study to investigate Efficacy and Safety of BGB-A317 in patients with Non-Small Cell Lung Cancer
- Previously treated Non-Small Cell Lung Cancer in the second or third line setting. MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Brazil, Bulgaria, China, Lithuania, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Turkey
- 2018-05-28